# US 11,433,117 B2 · Methods for regulating free fatty acid flux using fat specific protein 27 (FSP27) compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,433,117 B2
- Document ID: US11433117B2
- Status: Granted
- Kind: B2
- Application number: 16/620,661
- Filed: 2018-06-14
- Published: 2020-06-11
- Granted: 2022-09-06
- Earliest claimed: 2017-06-15
- Assignees: Ohio University
- Applicants: Ohio University
- Inventors: Vishwajeet Puri; John Kopchick; Vishva Sharma
- Web page: https://patentgrep.com/patent/US11433117B2

## CPC

- A61K 38/1709: {from mammals}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07K 14/4747: {Apoptosis related proteins}
- A01K 2217/052: inducing gain of function
- A01K 2227/105: Murine
- A01K 2267/0362: Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C07K 2319/42: containing a HA(hemagglutinin)-tag
- C07K 2319/60: containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

Methods and FSP27 compositions for treating and/or preventing metabolic disease and conditions associated insulin resistance, obesity, inflammation and dyslipidemia are described.

## Claims

### Claim 1

A method for treating a subject suffering from a metabolic disease associated with one or more of increased free fatty acids and lipotoxicity, comprising
directly administering to adipose fat cells and tissues of the subject in need thereof a recombinant peptide comprising SEQ ID NO: 2 in an amount sufficient to decrease lipolysis in the adipose fat cells and tissue without the need for gene delivery mechanisms,
wherein the metabolic disease is dyslipidemia.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the recombinant peptide decreases the expression and enzymatic activity of adipose tissue glycerol lipase (ATGL).

### Claim 3

A method for reducing the amount of visceral adipose fat in the subject, comprising
administering to the subject in need thereof an effective amount of a recombinant peptide comprising SEQ ID NO: 2, and
decreasing lipolysis in the visceral adipose fat cells and tissue.